In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 35, No. 15_suppl ( 2017-05-20), p. e23069-e23069
Abstract:
e23069 Background: Non-invasive diagnostic markers for patients with suspicious non-small cell lung cancer (NSCLC) may provide needed guidance on invasive diagnostic and therapeutic decisions. Thioredoxin reductase 1 (TrxR1) is a pivotal intracellular redox sensor and antioxidant enzyme, and plays an important part in tumor growth, progression, metastasis, and chemotherapy resistance. The goal of this study is to test the feasibility of developing plasma TrxR1 as a novel diagnostic marker for NSCLC. Methods: The plasma TrxR1 activity was determined spectrophotometrically by monitoring the NADPH-dependent production of 2-nitro-5-thiobenzoate at 412nm and at 37℃. All detection kits and automatic analyzer possess independent intellectual property rights, and have been widely used in breast cancer screening. Results: In this study, the plasma levels of TrxR1 were measured in 109 treatment-naïve resectable NSCLC patients and 15 individuals with benign tumor-like pulmonary diseases. Taking plasma TrxR1 activity of 5.0 as reference, the overall concordance rate was 58.1%, while those of CEA, CA199, CA125, NSE, CYFRA21-1 and SCC were 19.2%, 8.2%, 2.1%, 45.9%, 25.3% and 9.5%, respectively. Furthermore, using TNM staging (AJCC 7th ed.) as classifier, the concordance rates of TrxR1 in benign tumor-like pulmonary diseases, local and regional stage NSCLC subgroups were 53.3% (8/15), 57.5% (46/80) and 63.0% (17/27), respectively. A multipoint linear fitting correlation model was created, and the equation was TrxR1 = 5.716 + 0.4898*Stage. Conclusions: Our data suggest that plasma TrxR1 activity is a useful non-invasive diagnostic marker for NSCLC, and there may be a linear correlation between TrxR1 activity and pathological stage.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/JCO.2017.35.15_suppl.e23069
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2017
detail.hit.zdb_id:
2005181-5
Permalink